Perspective Therapeutics, Inc. Cash Flow Statement
CATX|10 years of annual SEC 10-K data (FY2013-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Perspective Therapeutics, Inc. used $8M in operating cash flow and negative free cash flow of $8M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.3M | -$5.1M | -$6.7M | -$6.2M | -$4.7M | -$3.7M | -$6.0M | -$3.9M | -$3.9M | -$3.5M |
| Depreciation & Amortization | - | $136.0K | $80.0K | $68.0K | $471.0K | $576.0K | $685.4K | $739.1K | $739.1K | $847.1K |
| Operating Cash Flow | -$7.7M | -$5.0M | -$5.7M | -$5.7M | -$3.9M | -$3.5M | -$3.2M | -$3.1M | -$3.1M | -$2.4M |
| Capital Expenditures | $266.0K | $444.0K | $337.0K | $549.0K | $479.0K | $133.0K | $19.0K | $6.6K | $6.6K | $55.1K |
| Free Cash Flow | -$8.0M | -$5.5M | -$6.0M | -$6.3M | -$4.4M | -$3.7M | -$3.2M | -$3.1M | -$3.1M | -$2.5M |
| FCF Margin | -274.1% | -230.4% | -261.3% | -400.8% | -91.5% | -79.3% | -77.0% | -67.7% | -67.7% | -49.4% |